Kimberly Bolin

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.

Cooley advised Vera Therapeutics, a clinical-stage biotechnology company, on its $115 million follow-on offering of common stock. Partners Jodie Bourdet and Kristin VanderPas led the Cooley team.

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Cooley has worked with Myovant Sciences since 2017 to develop and prosecute its owned and licensed patent portfolios and in intellectual property diligence leading up to Myovant’s acquisition by biopharmaceutical company, Sumitovant Biopharma. The total transaction value was $1.7 billion, with a total company value of $2.9 billion. Myovant aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy.

"Myovant's two products, ORGOVYX® and MYFEMBREE® have substantial potential. We believe the combination of Sumitovant and Myovant will strengthen Myovant's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health," said Hiroshi Nomura, CEO of Sumitomo Pharma. "

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.